Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
Author:
Affiliation:
1. Eli Lilly and Company, Indianapolis, IN, USA;
2. HealthCore Inc., Wilmington, DE, USA;
3. Eli Lilly Canada Inc., Toronto, ON, Canada;
4. Lilly USA LLC, Indianapolis, IN, USA
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1421146
Reference44 articles.
1. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
3. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
4. GLP-1 receptor agonists: a review of head-to-head clinical studies
5. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real‐world setting: A prospective, observational post‐marketing study;Diabetes, Obesity and Metabolism;2023-08-23
2. Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide;Journal of Diabetes Research;2023-06-01
3. Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study;Frontiers in Endocrinology;2022-10-31
4. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 ( SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RAs) : A pooled analysis of type 2 diabetes trials;Diabetes, Obesity and Metabolism;2022-09-23
5. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain;Frontiers in Endocrinology;2022-09-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3